ArticleNPJ breast cancer2023

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan.

Laura Alder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.